Review Article
Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review
Table 6
Characteristics of JAK inhibitor treatment.
| Patient | Gender | Age | Ocular inflammation | Inhibitor | Dosage | Treatment duration | Combined therapy | Side effects | Systematic symptoms | Ocular symptoms |
| 1 | Female | 59 | Keratitis | Tofacitinib | 5 mg bid | 1 month; Improved after 2 weeks | NA | No | Inactive | Inactive | 2 | Female | 45 | Anterior and intermediate uveitis | Tofacitinib | 11 mg daily | 4months; Improved after 1 month | MTX | No | Combination: Inactive Monotherapy: Active | Inactive | 3 | Female | 40 | Scleritis | Tofacitinib | 11 mg daily | 9 months; Improved after 1 week | MTX | No | No systematic symptoms | Inactive | 4 | Female | 22 | Anterior uveitis | Tofacitinib | 5 mg bid | 9 months | MTX 2.5 mg qod | No | NA | Inactive | 5 | Female | 45 | Scleritis | Tofacitinib | 5 mg bid | 6 months | Prednisone 5 mg qd | No | NA | Inactive | 6 | Female | 43 | Panuveitis | Tofacitinib | 5 mg bid | 7 months | NA | No | Inactive | Inactive | 7 | Female | 18 | Panuveitis | Baricitinib | 4 mg Qd | 5 months | MTX 15 mg qw Prednisone 12.5 mg qd | No | Active | Inactive | 8 | Female | 37 | Anterior uveitis | Baricitinib | 4 mg qd | 13 months | NA | No | Inactive | Active | 9 | Male | 21 | Panuveitis | Baricitinib | 4 mg qd | 4 months | MTX 15 mg qw Prednisone 7.5 mg qd | No | Active | Inactive | 10 | Male | 65 | Scleritis | Tofacitinib | 5 mg bid | Improvd after 1 month | MMF 500 mg bid Prednisone 2.5 mg qod | No | No systematic symptoms | Inactive | 11 | Male | 43 | Conjunctivitis | Baricitinib | 4 mg qd | 6month; Improvd after 2 weeks | MTX 25 mg qw Prednisolone 6 mg qd | Yes | NA | Inactive |
|
|
Note: NA: not available.
|